The RANKL/RANK/OPG Signaling Pathway Mediates Medial Arterial Calcification in Diabetic Charcot Neuroarthropathy

Agbor Ndip,1,2 Alfred Williams,2 Edward B. Jude,2,3 Ferdinand Serracino-Inglott,4 Steve Richardson,4 J.V. Smyth,4 Andrew J.M. Boulton,1,2 and M. Yvonne Alexander2

OBJECTIVE—The receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) signaling pathway (RANKL/RANK/OPG signaling) is implicated in the osteolysis associated with diabetic Charcot neuroarthropathy (CN); however, the links with medial arterial calcification (MAC) seen in people with CN are unclear. This study aimed to investigate the role of RANKL/OPG in MAC in patients with CN.

RESEARCH DESIGN AND METHODS—Enzyme-linked immunosorbent assay and Bio-plex multiarray technology were used to quantify a range of cytokines, including RANKL and OPG in sera from 10 patients with diabetes, 12 patients with CN, and 5 healthy volunteers. Human tibial artery segments were immunohistochemically stained with Alizarin red and human RANKL antibody. Human vascular smooth muscle cells (VSMCs) were also explanted from arterial segments for in vitro studies.

RESULTS—We demonstrate colocalization and upregulation of RANKL expression in areas displaying MAC. Systemic levels of RANKL, OPG, and inflammatory cytokines (interleukin-8, granulocyte colony-stimulating factor) were elevated in those with CN compared with diabetic patients and healthy control subjects. Human VSMCs cultured in CN serum showed accelerated osteoblastic differentiation (alkaline phosphatase activity) and mineralization (alizarin red staining) compared with cells treated with diabetic or control serum (P < 0.05). Coincubation with OPG, the decoy receptor for RANKL, attenuated osteogenic differentiation of VSMCs and was independent of a high calcium-phosphate milieu. The accelerated mineralization induced by RANKL and CN serum correlated with nuclear translocation of nuclear factor-κB, a process abrogated by OPG.

CONCLUSIONS—Our data provide direct evidence that RANKL/RANK/OPG signaling is modulated in patients with CN and plays a role in vascular calcification. This study highlights this pathway as a potential target for intervention. Diabetes 60:2187–2196, 2011

Vascular calcification is a strong independent predictor of cardiovascular mortality (1). In people with diabetes, medial arterial calcification (MAC) has emerged as a strong predictor of lower limb amputation and cardiovascular mortality (2,3). This may be to the result of an increase in arterial stiffness, pulse wave velocity, and systolic blood pressure, ultimately leading to reduced coronary perfusion and ventricular hypertrophy (4). MAC in people with diabetes is more common in those with peripheral neuropathy, who also display increased bone resorption (osteolysis) (5–7), typically seen in Charcot neuroarthropathy (CN). The signaling pathway of the receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL), and its decoy receptor osteoprotegerin (OPG) has been suggested as the link between vascular and bone metabolism (8,9). In fact, RANKL has been shown to mediate osteolysis in CN by stimulating osteoclastic differentiation of monocytes/macrophages, an effect that is attenuated by OPG, the decoy receptor (10). This has led to nascent theories implicating RANKL/OPG signaling as the potential pathogenetic basis for CN.

RANKL exists in two biologically active soluble forms secreted by T cells, endothelial cells, or osteoblasts or proteolytically cleaved from cell surfaces. RANKL binds to its target receptor RANK on cell surfaces (including vascular smooth muscle cells [VSMCs]) to generate multiple intracellular signals that regulate cell differentiation, function, and survival (8,11,12). In the vasculature, RANKL is expressed and upregulated in calcifying vascular cells (13) and enhances the recruitment and infiltration of cells that have been shown to stimulate VSMC mineralization (14).

Most of the evidence for a direct role of RANKL/OPG signaling in vascular calcification is derived from animal studies with limited human data. For instance, with the use of VSMCs from rat aorta, RANKL has been shown to increase VSMC calcification via activation of the alternate nuclear factor-κB (NF-κB) pathway (15). However, to enhance translational applications, we extend these data to human VSMCs and use of patient serum.

In diabetic CN, there is osteolysis and simultaneous vascular calcification, potentially leading to amputation (16,17). Therefore, the aim of this study was to determine the role of RANKL/OPG signaling in MAC in diabetic CN by using an in vitro model of vascular calcification.

RESEARCH DESIGN AND METHODS

Approval from the local research ethics committee was granted for the use of human tissue, and procedures were in accordance with institutional guidelines and the Declaration of Helsinki.

Patient serum. CN was confirmed clinically, supported by radiologic features as described previously (18). Serum was obtained via the antecubital fossa from 12 patients with CN at the time of diagnosis of acute stage disease, 10 patients with diabetes, and 5 nondiabetic volunteers, all matched for age, sex, and renal function. Ten milliliters of venous blood was withdrawn aseptically into sterile, heparinized tubes and centrifuged at 3,200 rpm for 15 min at 4°C. The resultant sera were measured in aliquots and stored at −80°C until future use. A recent analysis of patient serum, the Rancho Bernardo study, reported that storage at −70°C for up to 11 years did not affect RANKL or OPG concentrations (19).
**RANKL and OPG enzyme-linked immunosorbent assay.** Serum RANKL and OPG levels were measured using a sandwich ELISA technique according to the manufacturer’s protocol. According to the manufacturer, the intra-assay and interassay coefficients of variation for the soluble receptor (ampli-sRANKL, BI-20452, Lot K2; Charcot) ELISA assay are 8–9% and 3–6%, respectively, whereas the same values for the OPG assay (OPG, BI-20402 lot no. 873ac) are 4–40% and 7–8%, respectively (Biomedica Gruppe, Vienna, Austria). Absorbance was measured at 450 and 560 nm for the OPG and RANKL, respectively.

**Serum cytokine analysis.** A Bio-plex angiogenesis panel ("Pro-Human Angiogenic 9-plex plate" catalog number 171-304060) obtained from Bio-Rad Laboratories (Hercules, CA) was used according to the manufacturer’s protocol for analysis of angiogenin, vascular endothelial growth factor, hepatocyte growth factor, leptin, platelet endothelial cell adhesion molecule or CD-31, and follistatin and two inflammatory cytokines, granulocyte colony-stimulating factor (GCSF) and interleukin-8 (IL-8). The intra-assay and interassay coefficients of variation for the Bioplex angiogenesis assay were ≤15% and ≤25%, respectively, with an accuracy of 70–130%. Data were analyzed using Bio-Plex Manager software version 5.0.

**Tissue collection and immunohistochemistry for RANKL expression.** Segments of tibial artery were obtained from patients undergoing surgery (amputation) and used for immunohistochemistry and explantation of VSMCs as described previously (20). A panel of internal mammary artery (IMA) (deemed surplus to requirements from patients undergoing cardiac artery bypass graft surgery) and noncalciﬁed control artery. Arterial sections were stained using rabbit anti-human RANKL antibody (dilution 1:200 catalog number ab9057; AbCAM, Cambridge, U.K.) and a nonimmune serum (IgG) as negative control as described previously (20).

**Explaining and culture of human VSMCs.** Human VSMCs were obtained by tissue explantation (21) using smooth muscle cell growth medium obtained from PromoCell (PromoCell GmbH, Heidelberg, Germany) and subsequently maintained in regular growth medium (Dulbecco’s modiﬁed Eagle’s medium, high glucose, 4.5 g/L) containing 5% FBS, 10 mmol/L sodium pyruvate, 1.8 mmol/L CaCl₂, 100 U/mL penicillin, and 100 mg/mL streptomycin. All cells were used between passages three and eight.

**Induction and determination of calciﬁcation.** VSMC mineralization was induced using a modiﬁcation of the method described by Petrova et al. (22). Briefly, VSMCs were seeded in a 24-well plate at densities of 5 × 10⁴ cells/cm² and cultured in regular growth media until they reached 90% conﬁdence. Cells were then switched to osteogenic media, i.e., regular growth medium containing 2.6 mmol/L CaCl₂ and 5 mmol/L β-glycerophosphate for up to 7 days. Cells were treated with 1% serum from 1) healthy volunteers, 2) diabetic patients, or 3) patients with CN. Recombinant OPG (20 pmol/L) (catalog number GF120; Millipore Corporation, Hayward, CA) was added in a parallel set of experiments when cells were changed to osteogenic media and subsequently added each time the medium was replaced, as were vehicle control subjects. All experiments were performed in triplicate using three populations of VSMC, each from different patients. Alkaline phosphatase (ALP) activity assays and Alizarin red staining were carried out as described previously (20,21).

**Immunocytochemical localization of NF-eB.** Cells were seeded at a density of 5 × 10⁴ cells/cm² into four-well chamber slides (Laboratory-Tek Chamber Slides, Fisher Scientiﬁc UK LTD, Leicestershire, U.K.). At conﬁdence, they were subcultured for 1 h in osteogenic medium (OM) containing 5% Charcot serum, 20 pmol/L human recombinant soluble RANKL, and 20 pmol/L human recombinant soluble RANKL plus 20 pmol/L human recombinant OPG. Cells were ﬁxed in 4% paraformaldehyde, blocked in 5% goat serum/PBS and followed by incubation with primary rabbit anti-NF-eB antibody (1:500 dilution in 5% goat serum/PBS) and an Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody (Molecular Probes, Invitrogen, Paisley, U.K.). Rabbit IgG was used as intra-assay negative control. Cells were counterstained with 4 μg/mL DAPI and mounted in Vectashield mounting medium (Vector Laboratories, Inc., Burlingame, CA).

**Statistical analysis.** Each experiment was performed in triplicate with three different populations of human VSMCs explanted from different patients. Data were expressed as mean ± SD for the ELISA, Bio-plex, and cell culture assays (optical density [OD] and ALP activity). Differences between groups were analyzed using an unpaired Student t test (two groups) or a one-way ANOVA (three or more groups) as appropriate. Where multiple samples were compared using ANOVA, a post hoc Bonferroni analysis was performed to enable comparisons between groups. Data that were not normally distributed were log-transformed before performing statistical tests. A P value < 0.05 was considered statistically signiﬁcant.

**RESULTS**

The general clinical characteristics of the different patient groups are presented in Table 1.

---

### TABLE 1

| Age (years, mean ± SD) | Charcot | Diabetes | Healthy control subjects |
|------------------------|---------|----------|--------------------------|
| 56 ± 8                 | 58 ± 12 | 52 ± 14  |

Sex (male:female)

|                     | Charcot | Diabetes | Healthy control subjects |
|---------------------|---------|----------|--------------------------|
| 7.5                  | 6.4     | 3.2      |

Type 1: type 2 diabetes

Time since onset of diabetes (years)

|                     | Charcot | Diabetes | Healthy control subjects |
|---------------------|---------|----------|--------------------------|
| 10 ± 10              | 21 ± 12 | —        |

eGFR (ml/min)

|                     | Charcot | Diabetes | Healthy control subjects |
|---------------------|---------|----------|--------------------------|
| 53 ± 20              | 48 ± 29 | 52 ± 12  |

Localized RANKL expression and medial arterial calcification. To determine whether local RANKL expression was upregulated in calcified versus noncalcified arteries, sections of calcified tibial artery and noncalcified IMA were stained immunohistochemically with anti-human RANKL antibody and Alizarin red. The tibial artery displayed both medial and intimal calcification with positive RANKL staining detected within the vicinity of the calcified areas (B1, B2, and B3; C1 and C2). There was a distinct lack of positive RANKL staining in noncalcified areas (D1 and D2) and control IMA segments (A1, A2, and A3).

**Serum OPG and RANKL levels in patients with CN, diabetic patients, and healthy control subjects.** ELISA was performed to determine serum levels of RANKL and OPG in the two patient groups and control subjects. Serum OPG levels were higher in patients with CN (8.2 ± 2.7 pmol/L, ANOVA: P = 0.031) compared with diabetic patients (7.7 ± 3.3 pmol/L) and healthy control subjects (4.2 ± 0.7 pmol/L) (Fig. 2A). The Bonferroni post hoc test showed that OPG levels were higher in patients with CN versus control subjects (P = 0.01) and in diabetic patients versus control subjects (P = 0.029), but not significantly different between patients with CN and patients with diabetes (P = 0.638). In a similar trend, RANKL levels in patients with CN were 0.3 ± 0.042 pmol/L, approximately 8- and 15-fold higher than in patients with diabetes (0.04 ± 0.05 pmol/L) and healthy control subjects (0.02 ± 0.01 pmol/L), respectively (ANOVA test, P = 0.055). The Bonferroni test showed that patients with CN had higher serum levels of RANKL than diabetic patients (P = 0.033) or healthy control subjects (P = 0.063), but there were no signiﬁcant differences between diabetic patients and control subjects (P = 0.895) (Fig. 2B). Most important, the RANKL/OPG ratio was signiﬁcantly higher in patients with CN (36.8 ± 43.1 × 10⁻³) compared with those with diabetes (15.2 ± 4.9 × 10⁻³) and healthy control subjects (4.6 ± 3.1 × 10⁻³) (Fig. 2C).

The Bonferroni test showed that the RANKL/OPG ratio was higher in patients with CN than in diabetic patients (P = 0.019) and in patients with CN than in control subjects (P = 0.051), but differences between diabetic patients and control subjects were not signiﬁcant (P = 0.974).

**Serum protein analysis of inflammatory and angiogenic cytokines.** To determine whether an inflammatory milieu/stimulus may be modulated in patients with CN and thus driving elevated RANKL expression and subsequent secretion into systemic circulation in this group, we analyzed a panel of nine cytokines using a Bio-plex multianalyte suspension assay (Fig. 3). We demonstrated that two
proinflammatory cytokines (GCSF and IL-8) were significantly higher in patients with CN compared with diabetic patients and control subjects. This may well reflect an elevated inflammatory environment in patients with CN acting as the stimulus for elevated RANKL secretion. The serum levels of noninflammatory cytokines were not significantly different among the patients with CN, compared with patients with diabetes, and control patients. Charcot serum accelerates osteogenic differentiation and mineralization of VSMCs. Figure 4A shows results from the culture of human VSMCs at day 7 under the different conditions. Cells treated with Charcot serum displayed increased calcification as evidenced by Alizarin red staining. After dye elution and quantification, there were overall differences (ANOVA: P < 0.0001) in the extent of mineralization between the different culture conditions (Fig. 4C). Mineralization was higher in human VSMCs coincubated in Charcot serum (OD = 0.16 ± 0.01 vs. OM control subjects: 0.09 ± 0.003, P = 0.0003) compared with diabetic serum (OD = 0.15 ± 0.01 vs. OM, P = 0.0004) or healthy serum (OD = 0.14 ± 0.03 vs. OM, P = 0.037) (Fig. 4C).

Likewise, one-way ANOVA test showed that the early osteogenic differentiation marker, ALP, was significantly different (P < 0.0001) in human VSMCs subcultured in any of the three patient sera compared with OM that contained FBS (same concentration) in place of patient serum. The effect was most marked in Charcot than in diabetes serum. At day 7, the ALP activity of human VSMCs cultured in Charcot serum (49.9 ± 7.3) was approximately twofold higher than that induced by diabetes serum (29.8 ± 3.7 μmol/L phosphate/mg protein/min, P = 0.013) and threefold higher than either healthy serum (17.6 ± 10.1, P = 0.011) or OM control subjects (15.3 ± 5.4 μmol/L phosphate/mg protein/min, P = 0.037) (Fig. 4B).

Charcot serum and RANKL induce human VSMC mineralization in the absence of a high calcium phosphate milieu. To establish whether factors in Charcot serum or RANKL triggered the mineralization process per se or needed the presence of the elevated calcium and phosphate in the osteogenic conditions, cells were grown in ordinary growth medium to which the Charcot serum or RANKL was added. The VSMCs were shown to have a greater capacity to mineralize when cultured in the presence of Charcot serum (OD: 0.07 ± 0.003, P = 0.0009) or recombinant RANKL (OD 0.072 ± 0.003, P = 0.0002) compared with ordinary growth medium only (OD = 0.059 ± 0.002) (data not shown). The high levels of mineralization detected in the VSMCs cultured in the presence of Charcot serum or recombinant RANKL were similar to those induced by OM (OD = 0.075 ± 0.002).

OPG attenuates Charcot serum-induced osteoblastic differentiation of VSMCs. The anti-RANKL effect of OPG on VSMC osteoblastic differentiation and mineralization induced by Charcot and diabetes sera is shown in Fig. 5A–C. Compared with VSMCs subcultured in Charcot serum and RANKL, OPG had no effect on Charcot serum-induced mineralization (OD = 0.07 ± 0.003 vs. OM, P = 0.0009) (Fig. 5A). OPG attenuated Charcot serum-induced ALP activity (OD = 0.072 ± 0.003 vs. OM, P = 0.0002) (Fig. 5B). OPG also attenuated Charcot serum-induced RANKL expression (brown stain) in the vicinity of calcified areas of the tibial artery (B2 and B3) but negative staining of the control IMA (A2 and A3). Within the same TA, calcified areas (C, C1, and C2) showing upregulated RANKL expression are found adjacent to noncalcified areas (D, D1, and D2). (A high-quality digital representation of this figure is available in the online issue.)
Serum alone, coincubation of VSMCs with Charcot serum plus OPG resulted in an attenuation of osteoblastic differentiation (ALP activity, 20.9 ± 10.9) compared with those cultured in diabetes serum alone (Fig. 5B and C); the difference failed to achieve statistical significance. **Charcot serum and RANKL induce mineralization by NF-κB nuclear translocation in vitro.** To establish the downstream effects of Charcot serum or RANKL on transcription factors that may be involved in the mineralization of human VSMCs, we investigated the activation of the NF-κB pathway. VSMCs were subcultured for 1 h in Charcot serum (5% v/v) or recombinant RANKL (20 pmol/L) and stained immunocytochemically for the p65 component of NF-κB to detect its intracellular localization. Representative photomicrographs obtained after immunofluorescent staining for NF-κB are shown in Fig. 6A and B. After 1 h of culture of VSMCs in osteogenic media to which Charcot serum was added, NF-κB translocated from its cytoplasmic location to a predominantly nuclear and perinuclear location (Fig. 6A, images D and G). When VSMCs were incubated with recombinant RANKL in lieu of Charcot serum, nuclear translocation of p65 component of NF-κB was equally observed (Fig. 6B, images D and G).

**OPG blocks Charcot and RANKL-induced translocation of NF-κB.** To validate that the RANKL/OPG signaling involved translocation of NF-κB during mineralization of VSMCs, immunostaining was performed on subcultures of VSMCs (Charcot or RANKL) coincubated with OPG. The presence of OPG abrogated the NF-κB nuclear translocation induced by Charcot serum (Fig. 6A, images E and H) or recombinant RANKL (Fig. 6B, images E and H), thus confirming that NF-κB activation induced by Charcot serum directly involved RANKL/RANK/OPG signaling.

### DISCUSSION

Our results have demonstrated that RANKL/RANK/OPG signaling is implicated in human MAC in people with diabetes and CN. The RANKL immunolocalization data suggest a direct association between localized tissue expression of RANKL and MAC. Patients with CN also displayed high levels of inflammatory cytokines (IL-8, GCSF), OPG, RANKL, and particularly elevated RANKL/OPG ratio compared with diabetic patients or healthy volunteers. The high systemic level of RANKL enables it to bind to its receptor, RANK, and drive vascular smooth muscle cells into an osteoblastic differentiation pathway resulting in accelerated deposition of a mineralized matrix leading to MAC. This differentiation process is mediated by RANKL-induced translocation of NF-κB from the cytoplasm into the nucleus (Fig. 6A and B), leading to downstream nuclear mechanisms culminating in upregulated osteoblastic genes and increased ALP activity (Fig. 4B). The specific decoy receptor for RANKL, OPG, abrogates the osteoblastic differentiation of human VSMCs.

It should be emphasized that this was an in vitro study, and we did not seek to correlate the clinical stage of CN to the extent of MAC or the serum level of RANKL/OPG. This is an obvious limitation that will be addressed through future correlative clinical studies.

**High serum levels of inflammatory cytokines and RANKL/OPG ratio expressed in patients with CN.** The bone changes seen in CN are customarily thought to be triggered by events that enhance an inflammatory milieu, inducing monocytes into an osteoclastic differentiation program (10,22,23). We show that IL-8 and GCSF are two proinflammatory cytokines that are elevated in the
serum of patients with CN. Inflammatory cytokines induce activated T cells to secrete RANKL (24,25), and attendant to this, OPG levels increase to counteract the effects of RANKL (26). Figure 2 illustrates that both RANKL and OPG levels are higher in patients with CN. The current study is the first to provide data on systemic levels of RANKL and OPG in patients with CN. There is evidence in the literature reporting elevated levels of RANKL and OPG in other disease conditions associated with high bone turnover and vascular calcification, notably rheumatoid arthritis (27,28), Paget’s disease (29,30), and osteoporosis (31–33). In particular, most studies reveal that the ratio of RANKL/OPG is the more significant predictor of these disease conditions. Our data showing that the ratio of RANKL/OPG is significantly higher in patients with CN than in diabetic patients or nondiabetic control subjects (Fig. 2C) support these findings. Whether there is a cutoff ratio that may be diagnostic of CN or the ratio can be used to monitor disease activity remains to be elucidated. However, the high levels of the RANKL/OPG ratio can be anticipated to orchestrate deleterious effects on the vasculature as discussed below.

**Local expression of RANKL in the vicinity of MAC.** Local RANKL expression within the medial layer of the vasculature coincided with areas of MAC. Intense RANKL staining was observed in the vicinity of calcified areas confirmed by alizarin staining and a lack of staining in the negative tissue control (shown here as IMA) and the nonimmune IgG intra-assay control (results not shown). These findings agree with and support results from previous studies demonstrating increased RANKL protein and mRNA expression patterns in MAC (Monckeberg’s sclerosis) (34,35). Schoppet et al. (35) also found that OPG was predominantly adjacent to areas of calcification and areas of apoptosis throughout the whole circumference of their arterial specimens. However, the data for OPG immunostaining are less consistent in the literature. A study by Kaden et al. (13) on calcific aortic stenosis confirmed the positive correlation between RANKL immunostaining and calcification, but showed an inverse relationship between OPG immunostaining and calcified aortic stenosis. However, in the study by Kaden et al., decalcification was performed by placing tissue sections for 48 h in 270 mmol/L EDTA, a protocol that has not been replicated elsewhere and that may affect epitope exposure.

**Charcot serum and RANKL accelerate mineralization and osteoblastic differentiation of VSMCs via NF-κB nuclear translocation.** Our data demonstrate that explanted resident VSMCs undergo an osteogenic differentiation when cultured in media containing Charcot serum (Fig. 4B), a milieu that we show contains a high RANKL/OPG ratio (Fig. 2C). Our data suggest that systemic OPG is increased in patients with CN probably in response to and to mitigate the effects of high levels of RANKL. It is worth noting that although both OPG and RANKL levels were higher in diabetic patients compared with healthy control subjects, the RANKL/OPG ratio was not different between these two groups. It is therefore likely that elevated OPG levels in diabetic patients do compensate for elevated RANKL levels such that the ratio remains comparable to that of nondiabetic control subjects.

To further support the hypothesis that RANKL mediates MAC in patients with CN, immunocytochemical studies reveal that both RANKL- and Charcot-induced differentiation of human VSMCs are associated with the translocation of NF-κB from the cytoplasm into the nucleus (Fig. 6).

Of note, RANKL and Charcot serum enhanced mineralization of human VSMCs even in nonosteogenic conditions, i.e., normal growth medium without any added β-glycerophosphate or calcium. This finding refutes commonly held suggestions that MAC is merely a direct precipitation of inorganic (calcium and phosphate) ions when their levels are high in systemic circulation. Our data provide...
direct evidence of mineralization of human VSMCs in vitro by using nonosteogenic culture conditions. In fact, vascular calcification is an intricate and highly organized process involving cell differentiation, matrix deposition, and secondary ossification resulting in the formation of hydroxyapatite. In this study, we show that the cells are not only depositing a mineralized matrix but also actually switching their phenotype into osteoblastic cells as suggested by the elevated ALP activity, which is a marker of early osteogenic differentiation.

There is some controversy regarding the origin of cells that undergo osteogenic differentiation in MAC. Although some authors have suggested that circulating osteogenic precursor cells migrate from the blood through the vessel...
FIG. 5. A: Representative phase-contrast photomicrographs of human VSMCs at day 7 in culture for 7 days. Cells were cultured in OM and Charcot (5%) or diabetic (5%) sera (left) or 20 pmol/L recombinant OPG in addition to the same sera (right). The orange-red spots indicate mineralized nodule formation. White scale bar = 100 μm. B: ALP activity (μmol/L phosphate/mg protein/min) of cells at day 7. The inhibitory effect of OPG on the osteoblastic differentiation of human VSMCs is more marked in Charcot serum (#P = 0.011) compared with diabetic serum (*P = 0.120). C: Extent of mineralization of human VSMCs at day 7. The inhibitory effect of OPG on human VSMC mineralization is markedly significant in Charcot serum (##P = 0.004) but not significant in diabetic serum (**P = 0.249). (A high-quality digital representation of this figure is available in the online issue.)
wall to differentiate locally into osteoblastic cells, others have maintained that these osteoblastic cells originate from residential human VSMCs displaying marked phenotypic plasticity under specific stimuli. Our study supports the latter hypothesis because it demonstrates using an in vitro model that explanted human VSMCs of medial origin directly differentiate into an osteoblastic phenotype. Our data support those of Schoppet et al. (35), who found that the medial tissue surrounding calcified lesions in MAC contained only smooth muscle cells, whereas macrophages and lymphocytes were absent.

By using VSMCs from rat aortas, Panizo et al. (15) demonstrated that RANKL induced mineralization in a dose-dependent manner, an effect abrogated by OPG. Data reported in this study support and extend those of Panizo et al., implicating RANKL/OPG signaling in MAC by using smooth muscle cells from human origin.

OPG blocks RANKL- and Charcot-induced NF-κB nuclear translocation, and mineralization of human VSMCs. This study showed that OPG, a specific decoy receptor for RANKL, attenuated mineralization and osteoblastic differentiation of VSMCs induced by Charcot serum or RANKL. Our data also suggest a more pronounced effect of OPG on Charcot-mediated differentiation and mineralization of VSMCs compared with that induced by diabetes serum. Because OPG directly and specifically blocks the action of RANKL, these data provide additional evidence of RANKL/RANK signal modulation in CN-induced MAC.

FIG. 6. Fluorescent photomicrographs from immunocytochemical experiments. Human VSMCs were cultured to confluence in growth media and subsequently incubated for 1 h in (A) OM with Charcot serum (5% v/v) or coincubated with Charcot (5% v/v) serum plus 20 pmol/L recombinant OPG and (B) OM, including 20 pmol/L recombinant RANKL with or without plus 20 pmol/L recombinant human OPG. After 1 h, immunohistochemical staining to localize NF-κB was performed using rabbit anti-human p65 antibody. Goat anti-rabbit secondary antibody conjugated to a fluorescent dye (Alexa-Flour 488) was used to locate NF-κB staining (green) (D and E), whereas DAPI was used to stain the cell nucleus (blue) (A–C). Nonimmune rabbit IgG was used as negative antibody control (C, F, and I). Charcot serum induced nuclear translocation of NF-κB as seen by the intense perinuclear green stain (A, image G). Coincubation with OPG prevented the translocation of NF-κB, which remained predominantly cytoplasmic (A, image H). Likewise, RANKL induced nuclear translocation of NF-κB as seen by the intense perinuclear green stain (B, image G). Coincubation with OPG prevented the translocation of NF-κB, which remained predominantly cytoplasmic (B, image H). (A high-quality digital representation of this figure is available in the online issue.)
nuclear translocation of NF-κB was also abrogated by coincubation with OPG, thus lending support to the key mechanistic role played by NF-κB in RANKL-induced mineralization. In fact, binding of RANKL to its receptor RANK may activate the canonical or the alternative pathway of NF-κB signaling (36,37).

Tseng et al. (38) recently used a murine model of calcification to show that atherosclerotic calcification involves bone remodeling with simultaneous activation of both osteoclastic and osteoblastic differentiation. Although OPG attenuated Forskolin-induced osteoclastic differentiation, thus confirming similar reports by Mabilleau et al. (10), Tseng et al. reported that calcification was not abrogated by OPG and concluded that pathways different from RANKL/OPG signaling were implicated. This is not surprising because murine models of calcification, and likewise, atherosclerotic calcification, may involve different pathways than in humans. However, we provide evidence for the direct involvement of RANKL/OPG in human MAC as typified in CN.

In summary, patients with CN have high levels of inflammatory cytokines potentially modulating the RANKL/OPG signaling pathway. They further display elevated systemic (serum) RANKL levels and high RANKL/OPG ratio, driving VSMCs into an osteoblastic differentiation pathway, resulting in deposition of a mineralized matrix in vitro. Differentiation of VSMCs occurs via the RANKL/RANK signaling cascade, setting intracellular mechanisms involving the nuclear translocation of NF-κB. This study provides additional data demonstrating that MAC in CN is independent of the high calcium-phosphate microenvironment. Furthermore, OPG is shown to prevent nuclear translocation of NF-κB and abrogate differentiation and mineralization of VSMCs induced by RANKL or Charcot serum. On the basis of the findings from this study, a working model of MAC as occurs in patients with CN is proposed (Fig. 7).

When interpreted in the light of other studies confirming the crucial role of RANKL/OPG signaling in osteoclastic bone resorption (10), our data provide a potential unifying hypothesis for the underlying pathogenetic mechanisms resulting in diabetic CN. Abnormal RANKL/OPG signaling, therefore, may be proposed as the mechanism underpinning the paradoxical osteolysis and MAC seen in CN and similar disease conditions. This holds promise for the treatment of CN, especially because new drugs specifically targeting RANKL are already marketed for use in osteoporosis. Clinical trials are warranted to assess the efficacy of anti-RANKL therapy in the treatment or prevention of CN and vascular calcification.

ACKNOWLEDGMENTS

This study was funded partly by Diabetes UK project grants RD07/0003493 (Foot Problems in Dialysis Patients with Diabetes) and 03/0002584 (A Randomized Double-Blind Placebo-Controlled Trial of the Oral Bisphosphonate, Alendronate plus intravenous Pamidronate, in Active Diabetic Charcot Neuroarthropathy). Support was received from the Manchester National Institute for Health Research Biomedical Research Centre and Manchester Academic Health Science Centre.

No potential conflicts of interest relevant to this article were reported.

A.N. designed the study, performed all the experiments, researched data, and wrote and edited the manuscript.
REFERENCES

1. Niskanen L, Sluiter O, Suhonen M, Uusitupa MI. Medial arterial calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care 1994;17:1252–1256.

2. Lehto S, Niskanen L, Suhonen M, Rönnemaa T, Laakso M. Medial arterial calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:978–983.

3. Nelson RG, Golde DS, Everhart JE, et al. Lower-extremity amputations in NIDDM. 12-yr follow-up study in Pima Indians. Diabetes Care 1988;11:8–16.

4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938–942.

5. Young MJ, Adams JE, Anderson GF, Boulton AJM, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched nondiabetic control subjects. Diabetes 1993;33:615–621.

6. Chen NX, Moe SM. Arterial calcification in diabetes. Curr Diab Rep 2003;3:28–32.

7. Costacou T, Huskey ND, Edmundowicz D, Stolik R, Orchard TJ. Lower-extremity arterial calcification as a correlate of coronary artery calcification. Metabolism 2006;55:1689–1696.

8. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004;74:103–106.

9. Jeffcoate W. Vascular calcification and osteolysis in diabetic nephropathy—is RANKL the missing link? Diabetologia 2004;47:1488–1492.

10. Mabileau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclast activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008;51:1035–1040.

11. Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041–1048.

12. Walsh MC, Choi YY. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003;14:251–263.

13. Kaden JJ, Bickelhaupt S, Grobolzh R, et al. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004;35:567–566.

14. Breuil Y, Schmid-Antomarchi H, Schmid-Antomarchi H, Rezonzon R, Eulier-Ziegler L, Ross B. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J 2003;17:1751–1753.

15. Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041–1048.

16. Shaw JE, Boulton AJM. The Charcot foot. The Foot 1995;5:65–70.

17. Sanders LF, Frykberg RG. Charcot foot. In The Diabetic Foot. 5th ed. Levin ME, Onew LIW, Bouker JH. St. Louis, Mosby-Yearbook Inc., 1993, p. 149–180.

18. Eude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001;44:2032–2037.

19. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007;156:555–562.

20. Wilkinson FL, Liu Y, Rucka AK, et al.; Contribution of VCAF-positive cells to neovascularization and calcification in atherosclerotic plaque development. J Pathol 2007;211:362–369.

21. Kirton JP, Wilkinson FL, Canfield AE, Alexander MY. Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res 2006;98:1264–1272.

22. Petrova NL, Moniz C, Elias DA, Buxton-Thomas M, Bates M, Edmonds ME. Is there a systemic inflammatory response in the acute Charcot foot? Diabetes 2007;30:987–998.

23. Uccioli L, Sinistro A, Almenighi C, et al. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 2010;33:350–355.

24. Saldenbergen Kermanach N, Bessis N, Cohen-Solal M, De Vermeulj MC, Boissier MC. Osteoprotegerin and inflammation. Eur Cytokine Netw 2002;13:144–153.

25. Lam J, Abu-Amer Y, Nelson CA, Fremont DH, Ross FP, Teitelbaum SL. Tumor necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis 2002;61(Suppl 2):ii82–ii83.

26. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005;366:2058–2061.

27. van Tuyl LHD, Voskuyl AE, Boers M, et al. Baseline RANKL/OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010;69:1623–1628.

28. Geusens PP, Landewé RMB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54:1772–1777.

29. Martini G, Gennari L, Merloti D, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget’s disease of bone. Bone 2007;40:457–463.

30. Alvarez L, Peris P, Guañabens N, et al. Serum osteoprotegerin and its ligand in Paget’s disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003;48:824–828.

31. Pino AM, Rios S, Astudillo P, et al. Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res 2010;25:492–498.

32. Mezquita-Raya P, de la Higuera M, García DF, et al. The contribution of inflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. J Pathol 2007;206:2993–2999.

33. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor obstex is required for osteoblast differentiation and osteoporosis. J Biol Chem 2010;285:29925–29931.